LYEL Lyell Immunopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1806952 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-63.4%
TTM net income YoY21.6%
TTM EPS YoY44.6%
Revenue 3-yr CAGR-93.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,783,580.0%
Net margin-1,701,066.7%
FCF margin-933,100.0%
EBITDA margin-1,723,546.7%
Returns
ROE-97.8%
ROA-74.8%
ROIC (approx.)-138.0%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets29.6%
Debt / equity0.00x
Current ratio4.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue4,766.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3,000 | $4,000 | $2,000 | $6,000 | $15,000 | $8,000 | $7,000 | $11,000 |
| R&D expense | $40.90M | $39.52M | $36.60M | $52.20M | $28.17M | $34.86M | $43.45M | $48.67M |
| SG&A expense | $9.30M | $9.58M | $9.55M | $10.62M | $10.69M | $9.79M | $14.05M | $14.52M |
| Operating income | -$48.30M | -$47.34M | -$44.26M | -$127.64M | -$37.25M | -$47.14M | -$57.37M | -$201.15M |
| Net income | -$45.53M | -$44.76M | -$24.15M | -$140.72M | -$38.85M | -$42.68M | -$52.20M | -$191.94M |
| EBITDA | -$46.24M | -$45.12M | -$41.93M | -$125.25M | -$34.69M | -$44.01M | -$53.93M | -$196.12M |
| EPS (basic) | -1.86 | -1.92 | -1.10 | — | -2.13 | -2.89 | -3.54 | — |
| EPS (diluted) | -1.86 | -1.92 | -1.10 | — | -2.13 | -2.89 | -3.54 | — |
| Weighted avg. shares (diluted) | 24.44M | 23.36M | 21.88M | — | 18.27M | 14.79M | 14.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $92.05M | $72.98M | $90.77M | $60.18M | $123.58M | $98.80M | $120.33M | $107.29M |
| Short-term investments | $85.05M | $131.12M | $163.25M | $187.04M | $196.05M | $177.99M | $180.85M | $264.93M |
| Current assets | $186.21M | $213.54M | $267.30M | $260.94M | $328.20M | $282.21M | $309.18M | $379.59M |
| PP&E, net | $28.53M | $30.51M | $32.72M | $34.77M | $36.72M | $39.12M | $44.20M | $48.20M |
| Total assets | $273.85M | $311.15M | $350.63M | $340.05M | $407.96M | $385.45M | $429.80M | $490.86M |
| Current liabilities | $46.27M | $39.87M | $36.95M | $49.41M | $31.88M | $36.90M | $41.28M | $53.79M |
| Total liabilities | $81.13M | $77.34M | $76.96M | $91.85M | $78.84M | $86.53M | $93.28M | $108.03M |
| Shareholders' equity | $192.72M | $233.81M | $273.67M | $248.20M | $329.12M | $298.92M | $336.52M | $382.82M |
| Shares outstanding | 24.58M | 23.40M | 23.33M | 21.25M | 19.29M | 14.83M | 295.28M | 14.74M |
| Cash flow statement | ||||||||
| Operating cash flow | -$34.57M | -$33.92M | -$38.51M | -$32.25M | -$28.58M | -$34.46M | -$54.74M | -$47.24M |
| Capital expenditure | $66,000 | $256,000 | $89,000 | $304,000 | $62,000 | $168,000 | $246,000 | $44,000 |
| Free cash flow | -$34.63M | -$34.18M | -$38.60M | -$32.55M | -$28.64M | -$34.63M | -$54.98M | -$47.29M |
| Investing cash flow | $53.59M | $15.62M | $17.38M | -$31.36M | $3.35M | $12.65M | $69.47M | $53.51M |
| Financing cash flow | $41,000 | $522,000 | $51.72M | $222,000 | $50.00M | $183,000 | $1,000 | $437,000 |
| Depreciation & amortization | $2.05M | $2.22M | $2.33M | $2.40M | $2.57M | $3.13M | $3.44M | $5.03M |
| Stock-based compensation | $4.51M | $4.53M | $4.29M | $25.57M | $5.23M | $5.00M | $6.02M | $8.08M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.